A Study Of Galcanezumab In Participants With Episodic Cluster Headache

Inclusion Criteria:

• Have a diagnosis of cluster headache as defined by International Headache Society (IHS) International Classification of Headache Disorders (ICHD)-3 beta guidelines witha history of episodic cluster headache with at least two cluster periods lasting from 7 days to 1 year (when untreated) and separated by pain-free remission periods of >=1month.

• Participants are able to distinguish cluster headache attacks from other headaches.

Exclusion Criteria:

• Current enrollment in or discontinuation within the last 30 days from, a clinicaltrial involving any investigational drug or device.

• Current use or any prior exposure to any calcitonin-gene-related peptide (CGRP)antibody, any antibody to the CGRP receptor, or antibody to nerve growth factor (NGF).

• Are taking indomethacin and/or are suspected of having another distinct trigeminalautonomic cephalalgia.

• A history of migraine variants that could implicate or could be confused withischemia.

• Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeuticproteins.

• A history or presence of other medical illness that indicates a medical problem thatwould preclude study participation.

• Evidence of significant active or unstable psychiatric disease, in the opinion of theinvestigator.

• Women who are pregnant or nursing.